Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779 is registered in ClinicalTrials.gov with Pharvaris Netherlands B.V. as lead sponsor.

NCT NCT06343779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06343779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults With Hereditary Angioedema
Lead sponsor
Pharvaris Netherlands B.V.
Phase
Phase 3
Overall status
Completed
Start date
February 26, 2024
Completion date
October 17, 2025
Enrollment
134 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

c1 esterase inhibitor [c1-inh] deficiency, c1 esterase inhibitor deficiency, c1 esterase inhibitor, deficiency of, c1 inhibitor deficiency, hereditary angioedema, hereditary angioedema - type 1, hereditary angioedema - type 2, hereditary angioedema - type 3, hereditary angioedema attack, hereditary angioedema type i, hereditary angioedema type ii, hereditary angioedema type iii, hereditary angioedema types i and ii, hereditary angioedema with c1 esterase inhibitor deficiency